P2RY12 and atrial fibrillation: In the WOEST-3 trial [31], 2000 AF patients undergoing PCI are being randomized to guideline-directed therapy (edoxaban plus P2Y12 inhibitor plus limited duration of aspirin) or a 30-day DAPT strategy (P2Y12 inhibitor plus aspirin) followed by DAT (edoxaban plus P2Y12 inhibitor) for the subsequent 5–11 months.